A Randomized Trial to Assess the Efficacy and Safety of ABT-126, a Selective α7 Nicotinic Acetylcholine Receptor Agonist, in the Treatment of Cognitive Impairment in Schizophrenia.

A Randomized Trial to Assess the Efficacy and Safety of ABT-126, a Selective α7 Nicotinic Acetylcholine Receptor Agonist, in the Treatment of Cognitive Impairment in Schizophrenia.

Item
http://www.wikidata.org/entity/Q39949505
The α7 Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b Study.Alpha-7 nicotinic agonists for cognitive deficits in neuropsychiatric disorders: A translational meta-analysis of rodent and human studies.Pharmacokinetic Limitations on Effects of an Alpha7 Nicotinic Receptor Agonist in Schizophrenia: Randomized Trial with an Extended Release Formulation.The impact of genetics on future drug discovery in schizophrenia.Placebo Response and Practice Effects in Schizophrenia Cognition Trials.Managing Negative Symptoms of Schizophrenia: How Far Have We Come?Alpha7 nAChR Agonists for Cognitive Deficit and Negative Symptoms in Schizophrenia: A Meta-analysis of Randomized Double-blind Controlled TrialsFirst in human trial of a type I positive allosteric modulator of alpha7-nicotinic acetylcholine receptors: Pharmacokinetics, safety, and evidence for neurocognitive effect of AVL-3288.The current agonists and positive allosteric modulators of α7 nAChR for CNS indications in clinical trials.Effects of varenicline on cognitive performance in heavy drinkers: Dose-response effects and associations with drinking outcomes.Verbal learning and hippocampal dysfunction in schizophrenia: A meta-analysis.Efficacy of different types of cognitive enhancers for patients with schizophrenia: a meta-analysisEvolution in Neuromodulation-The Differential Roles of Acetylcholine in Higher Order Association vs. Primary Visual Cortices
P2860

A Randomized Trial to Assess the Efficacy and Safety of ABT-126, a Selective α7 Nicotinic Acetylcholine Receptor Agonist, in the Treatment of Cognitive Impairment in Schizophrenia.

Item
http://www.wikidata.org/entity/Q39949505
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
A Randomized Trial to Assess t ...... e Impairment in Schizophrenia.
@en
A Randomized Trial to Assess t ...... e Impairment in Schizophrenia.
@nl
type
label
A Randomized Trial to Assess t ...... e Impairment in Schizophrenia.
@en
A Randomized Trial to Assess t ...... e Impairment in Schizophrenia.
@nl
prefLabel
A Randomized Trial to Assess t ...... e Impairment in Schizophrenia.
@en
A Randomized Trial to Assess t ...... e Impairment in Schizophrenia.
@nl
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
A Randomized Trial to Assess t ...... ve Impairment in Schizophrenia
@en
P2093
P304
P31
P356
10.1176/APPI.AJP.2015.15010093
P407
P433
P478
P50
P577
P698
P921